Results 241 to 250 of about 67,878 (296)

Splenic haemangiosarcoma in a cat treated with splenectomy and metronomic thalidomide. [PDF]

JFMS Open Rep
Coates V, Alves Nores V, Caulfield S, Purzycka K, Plested M, Salord Torres X.   +5 more
europepmc   +1 more source

Overall survival in multiple myeloma in Brazil: A cohort of 16 years. [PDF]

Hematol Transfus Cell Ther
Oliveira DMDS, de Freitas ICM, Prata WM, Zuppo Laper I, Azevedo PS, Sabino AP, Itonaga MY, de Souza CA, Cherchiglia ML, Teodoro JA, Acurcio FA, Junior AAG.   +11 more
europepmc   +1 more source

Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh. [PDF]

Cureus
Alam AFMM, Azad MAK, Hassan MM, Islam S, Islam MN, Choudhury MR, Haq SA.   +6 more
europepmc   +1 more source

Targeted degradation of EGFR 19Del by PROTACs suppresses tumor growth in non-small-cell lung cancer. [PDF]

Front Pharmacol
Piao L, Gao Y, Su Y, Li Q, Yuan X, He W, Zhao W, Kulpakko J, Cha PC, Chang S, Kong R.   +10 more
europepmc   +1 more source

Upadacitinib treatment of refractory livedoid vasculopathy: a case report and literature review. [PDF]

An Bras Dermatol
Zheng J, Liang X, Huang X, Liao J.
europepmc   +1 more source

A conversation with Keith McCrae, MD, staff and professor of molecular medicine, Cleveland Clinic. [PDF]

J Clin Transl Sci
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

THALIDOMIDE

Dermatologic Clinics, 2001
Thalidomide has been successful in the treatment of several dermatologic conditions unresponsive to other agents. Further experience may lead to a better understanding of its mechanism of action in these various diseases. Thalidomide should be considered an extremely valuable therapeutic option in selected patients when the benefits clearly outweigh ...
C L, Radomsky, N, Levine
openaire   +4 more sources

Thalidomide-Associated Thrombocytopenia

Annals of Pharmacotherapy, 2005
OBJECTIVE To report thrombocytopenia in a patient prescribed thalidomide for multiple myeloma (MM). CASE SUMMARY A 70-year-old woman was diagnosed in 2003 with MM. At diagnosis, melphalan 0.25 mg/kg/day and prednisolone 2 mg/kg/day were started; however, the patient became refractory to therapy.
Duyvendak, M, Naunton, M., Kingma, B.J, Brouwers, J.R.B.J.   +3 more
openaire   +3 more sources